MOTS-c and SS-31 Are Not Two Versions of the Same Idea. One Is a Signal, One Is a Scaffold.

They are not two versions of one compound.

I sell one of them. MOTS-C 40mg is on our site, purity stated at ≥99%, COA attached. I have no commercial interest in SS-31 or elamipretide at all, no listing, no supplier, no plans. Weight everything below accordingly. I keep coming back to this pair because the mistake people make when they compare them is not a preference mistake. It is a category mistake, and category mistakes cost more, because you end up misreading whatever you observe.

Ask "which mitochondrial peptide is better" and you have already lost. Both names live in the mitochondrion. That is the extent of the overlap.

Signal vs. Scaffold

Two questions, in this order.

One: does the compound carry a message out of the mitochondrion, or hold structure inside one?

Two: does its literature live in models of metabolic dysregulation, or models of mitochondrial damage?

MOTS-c answers signal, dysregulation. SS-31 answers scaffold, damage.

The cleanest documented example of MOTS-c behaving like a signal is not a hand-wave about metabolism. Biotinylated MOTS-c pull-down with mass spectrometry identified BACH1, a transcription repressor, as a direct binding partner. MOTS-c binds competitively at the D560 residue, displaces the deubiquitinase USP7, and pushes BACH1 into K33-linked polyubiquitination and proteasomal degradation. In human umbilical vein endothelial cells stressed with taurocholic acid, MOTS-c attenuated oxidative stress and apoptosis, and overexpressing BACH1 abolished that protection, which pins the effect to the BACH1/SLC25A51 axis. That is a message with a delivery address. It is also cells in a dish, so hold it loosely.

SS-31, elamipretide, is a tetrapeptide: D-Arg-Dmt-Lys-Phe-NH2. Its entire design premise is going in and staying in. The net +3 charge and the spatial arrangement of its cationic and aromatic side chains are described as required for selective interaction with cardiolipin at the inner mitochondrial membrane.

You can tell what the field believes by how it builds the analogues. RI-4FPhe-SS31 is a proposed retroinverso version with a 4-fluorophenylalanine substitution: the backbone flip to resist endogenous peptidases, the fluorine to block CYP450-mediated aromatic hydroxylation, two separate metabolic vulnerabilities of the parent. The prediction is a longer plasma half-life while preserving that +3 charge and that side-chain geometry.

Nobody protects geometry on a messenger. You protect geometry when the molecule has to fit something.

One is a text message. The other is a load-bearing beam. I am pointing at the metaphor rather than letting you find it, because people keep reading these two as trim levels of the same vehicle.

The literature sorted itself years ago

Look at where each name actually appears.

Elamipretide shows up in damage models, and the numbers are structural. In a rat model of heart failure with preserved ejection fraction, skeletal muscle showed reduced cardiolipin (-6.8%, P=0.007), altered cardiolipin maturation via tafazzin expression, titin hyperphosphorylation, fiber atrophy. Twelve weeks of elamipretide was associated with improved whole-muscle contractile function in the soleus (+8.2%, P=0.041) and EDL (+10.9%, P=0.016), reduced titin phosphorylation, and limited atrophy. Single-fiber soleus function went up 173.2%. Single-fiber EDL did not reach significance, and that belongs in the same sentence.

In cultured H9C2 cardiomyoblasts, 1 µM SS-31 partially reduced doxorubicin-induced senescence staining from 51.4% to 35.8% of cells, and in a 10 Gy radiation model over 7 days from 67% to 38%. It prevented p16 and p21 rises, reduced secreted TNF-α, IL-6 and IL-1β, cut mitochondrial ROS, reversed the BAX/bcl-2 ratio. It did not prevent doxorubicin-induced cell cycle arrest. In porcine oocytes, 1 µM raised maturation rates (78.3% vs 55.2%) and blastocyst formation (7.6% vs 2.8%), with lower ROS and DNA fragmentation. In bovine oocytes, membrane potential rose while ATP content came out lower than controls, which is exactly the kind of wrinkle that gets left out of a product description.

MOTS-c shows up somewhere else entirely. A review of mitochondrial dysfunction in ARDS lists it among mitochondria-targeted agents that have shown promise in preclinical models, and the pathology that review describes is signalling vocabulary: impaired mitophagy, Drp1-mediated fission, mtDNA release, cGAS/STING and NLRP3 inflammatory pathways, a metabolic shift from oxidative phosphorylation toward aerobic glycolysis.

The human MOTS-c data I can point to is associational. In 160 adults with kidney failure compared with 80 controls, the disease group had higher advanced glycation end-products and lower mitochondrial-derived peptides including MOTS-c, and serum MOTS-c stayed inversely associated with the AGEs/sRAGE ratio in multivariable analysis. That is a cross-sectional pattern. It tells you nothing about what happens when you add MOTS-c to a person.

Elamipretide, by contrast, has been through clinical investigation in primary mitochondrial myopathy and other rare conditions, and the honest summary of those signals is the one the reviewers give: variable, more consistent within mitochondrial subgroups, still requiring consolidation in hard clinical endpoints. I am not going to assert its regulatory status from memory. What I will say plainly is that MOTS-c's human record is thinner than elamipretide's, and MOTS-c is the one I sell.

Also, mechanism is not a mood. In mice, elamipretide dose-dependently decreased locomotor activity, showed no effect on anxiety-related behavior, and potentiated cocaine conditioned place preference. Targeted does not mean tidy.

Where the comparison stops being useful

Right here. If one compound acts on signalling and the other on structure, and their literatures live in different disease models, you are not choosing between alternatives. You are holding two unrelated tools and asking which screwdriver is the better hammer.

Which means cross-reading is the real hazard. Elamipretide's cardiolipin and cristae work says nothing about MOTS-c. MOTS-c's transcriptional story says nothing about SS-31. Anyone selling you the category instead of the compound is counting on you not noticing.

And before I raise the standard on anyone, here is mine. Our MOTS-C 40mg listing carries an attached COA with stated ≥99% purity, identity confirmed by LC-MS with the mass-confirmation spectra printed, and the external laboratory that ran it named on the certificate. That certificate does not report sterility or endotoxin. Those are separate assays and we do not currently commission them. That is a real gap, it is mine, and I would rather you hear it from me.

Read the full MOTS-c listing, COA and stated purity included, before you decide whether it belongs in your research plan at all.